TONIX Pharmaceuticals Sees 28.53% Share Price Surge
By ATTN Desk · Editorial oversight: Sean Han
TONIX Pharmaceuticals Holding Corp. (NASDAQ: TNXP)
Introduction
TONIX Pharmaceuticals Holding Corp. is a biopharmaceutical company headquartered in Chatham, New Jersey. Founded in 2011, TONIX develops and commercializes therapies for central nervous system (CNS) disorders, rare diseases, immunology, and infectious diseases. The company markets two FDA-approved products for acute migraine management and advances a pipeline that spans preclinical stages to NDA submissions.
Corporate Structure and Workforce
- Headquarters: Chatham, New Jersey, USA
- Founded: 2011
- Chief Executive Officer: Dr. Seth Lederman, M.D.
- Employee Count: 51–200 (per LinkedIn)
- Collaborations:
- Government institutions (e.g., U.S. Department of Defense)
- Academic and non-profit research organizations (e.g., University of Geneva, Massachusetts General Hospital)
- Biotech licensing partners
Recent Developments and News
-
May 27, 2025
- Share price closed at $37.18, reflecting an increase of 28.53% on a trading volume of 1,414,406 shares (Exchange: NASDAQ).
-
May 21, 2025
- Filed Form 8-K reporting items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits).
-
May 22, 2025
- Issued a press release outlining corporate updates and upcoming milestones.
-
August 15, 2025
- PDUFA goal date for TNX-102 SL (sublingual cyclobenzaprine) NDA decision for the management of fibromyalgia.
-
March 11, 2025
- Scheduled a presentation at the 2025 Virtual Investor Summit, focusing on TNX-102 SL and other pipeline assets.
Financial and Strategic Analysis
| Metric | Value | Source (as of 5/27/2025) |
|---|---|---|
| Share Price | $37.18 | User-provided stock data |
| Day's Change | +28.53% | User-provided stock data |
| Volume | 1,414,406 | User-provided stock data |
| Market Capitalization | $272.2 million | Yahoo Finance |
| Trailing P/E | 0.10 | Yahoo Finance |
| Revenue (TTM) | $10.04 million | Yahoo Finance |
| Net Income (TTM) | –$131.93 million | Yahoo Finance |
| Total Cash (MRQ) | $131.72 million | Yahoo Finance |
| Total Debt/Equity (MRQ) | 0.31% | Yahoo Finance |
| Price/Sales (TTM) | 6.37 | Yahoo Finance |
| Price/Book (MRQ) | 1.17 | Yahoo Finance |
Strategic Highlights:
- TNX-102 SL: Completes two Phase III trials; NDA is under review with FDA, with a decision expected on August 15, 2025.
- Migraine Products: Zembrace® SymTouch® and Tosymra® generate revenue.
- Pipeline Diversity: Includes programs in CNS (e.g., for acute stress disorder), immunology (TNX-1500 for preventing organ transplant rejection), infectious diseases (TNX-801 vaccine for smallpox/monkeypox), and rare genetic disorders (TNX-2900 for Prader-Willi syndrome).
- Cash Position: $131.7 million in cash is expected to support ongoing clinical programs through key near-term catalysts.
Market Position and Industry Context
- NASDAQ Biotechnology Index: Added December 2021.
- Therapeutic Areas:
- Central Nervous System (CNS-related conditions)
- Rare Diseases
- Immunology
- Infectious Diseases (COVID-19, smallpox/monkeypox)
- Competitive Landscape: Operates in the micro- and small-cap biopharma segment alongside peers developing CNS and rare disease therapies.
- Collaborative Model: Combines in-house R&D with academic, government, and industry partnerships to mitigate development risks.
tl;dr
- On May 27, 2025, TNXP shares rose 28.53% to $37.18 on 1.4 million shares traded.
- NDA for TNX-102 SL (fibromyalgia) is under FDA review, with a PDUFA date set for August 15, 2025.
- Form 8-K was filed on May 21, 2025, covering Regulation FD disclosures and other events.
- $131.7 million cash position supports multiple clinical and preclinical programs across CNS, immunology, and infectious diseases.
- Next catalysts include the FDA decision in August and Phase II initiations for select pipeline assets.